Show simple item record

dc.contributor.authorAlonso-Ojembarrena, Almudena
dc.contributor.authorOulego‑Erróz, Ignacio
dc.date.accessioned2023-10-10T12:48:18Z
dc.date.available2023-10-10T12:48:18Z
dc.date.issued2022-12-06
dc.identifier.issn0012-3692
dc.identifier.urihttp://hdl.handle.net/10498/29411
dc.description.abstractLaser photocoagulation has been the standard of treatment of ROP for many years. However, since its introduction in 2007, the use of intravitreal injection of anti-VEGF agents has been incorporated to ROP management. Several trials have shown that anti-VEGF drugs (bevacizumab, ranibizumab) may be superior to laser photocoagulation for type I ROP (zone I [any stage with plus disease] or zone I-stage 3 without plus disease)es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceChest. vol. 162, nº 6, December 2022, pp. 1231 - 1232es_ES
dc.subjectRetinopathy of prematurity (ROP)es_ES
dc.subjectBevacizumabes_ES
dc.subjectRetinopathy of Prematurityes_ES
dc.titleIntravitreal Bevacizumab for Retinopathy of Prematurity: Another Hit to the Immature Lung?es_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.description.physDesc2 páginases_ES
dc.identifier.doi10.1016/j.chest.2022.06.032
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional